Research Trials
If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.334.4773, or email us at clinicaltrials@nebraskacancer.com.
Download All Current Trials
-
Cancer Type:
-
Biomarker:
-
Phase:
-
Keyword:
-
Serminox, SMX 22-002, Elaine III
A Phase 3 Study comparing the efficacy and safety of the combination of Lasofoxifene and Abemaciclib to the combination of Fulvestrant and Abemaciclib for the treatment of pre and post menopausal women and men with locally advanced or metastatic ER+/Her2- Breast cancer with ESR1 MutationCancer Type: BREAST
Biomarkers: ESR1
Phase: 3
-
AstraZeneca Triton
A Phase 3b, Study to assess the efficacy of Durvalumab plus Trememlimumab vs Pembrolizumab in combination with platinum based chemotherapy for 1st line treatment in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRASCancer Type: Lung NSCLC
Biomarkers: STK11, KEAP1, KRAS
Phase: 3
-
SLC-391-102, Skylite
Phase 1b/2 study of SLC-391, an AXL inhibitor, in ccombination with pembrolizumab in subjects wiht advanced or meastatic NSCLCCancer Type: Lung NSCLC
Lines of Therapy: 4, 3, 2
Biomarkers: PD-L1+
Phase: 1b, 2
View Details on ClinicalTrials.gov
-
VMT-a-NET
Phase 1/2a first in human study of VMTaNET Targeted Alpha Particle Therapy for advanced SSTR2 Positive Neuroendocrine TumorsCancer Type: Neuroendocrine
Biomarkers: SSTR2
View Details on ClinicalTrials.gov
-
PROCLAIM (201707770)
Phase 3 Randomized Placebo controlled double blind study of Romiplostim for the treatment of chemotherapy induced thrombocytopenia in patients receiving chemotherapy for treatment of NSCLC, Ovarian, Breast CancerCancer Type: BREAST, OVARIAN, Lung NSCLC
Phase: 3
View Details on ClinicalTrials.gov
-
REC-4881-221, Recursion
Phase II, open label stufy of REC 4881 in participants with unresectable locally advanced or metastatic tumors with AXIN1 or APC mutationsCancer Type: Solid tumor
Biomarkers: AXIN1, APC, APN
Phase: 2
View Details on ClinicalTrials.gov
-
MK6482-022
Double-Blind, randomized, phase III trial to compare safety and efficacy of Belzutifan (MK6482) plus Pembrolizumab (MK3475) vs. placebo plus Pembrolizumab in adjuvant treatment of clear cell renal cell carcinoma post nephrectomyCancer Type: Renal
Phase: 3
View Details on ClinicalTrials.gov
-
NKT2152-101 substudy only
A Phase I/II, open label dose escalation and expansion trial of NKT2152, an orally administered HIF-2a inhibitor, to investigate safety, pharmacokinetics, pharmacodynamics, and clinical activity in patients with advanced clear cell renal cell carcinomaCancer Type: Renal
Phase: 1, 2
View Details on ClinicalTrials.gov
-
PLB1004 - I (US01-BAB22228)
Phase 1, open label, multidose, dose escalation and expansion study of the oral EGFR inhibitor PLB1004 in NSCLCCancer Type: Lung NSCLC
Lines of Therapy: 3, 2
Biomarkers: EGFR
Phase: 1
View Details on ClinicalTrials.gov
-
GO44096 (Skyscraper-11)
Phase 2, IV fixed dose combination of Tiragolumab and Atezolizumab in patients with llocally advanced, recurrent, or metastatic solid tumorsCancer Type: MELANOMA, Renal, Urothelial, Esophageal, Lung NSCLC, Head and Neck Squamous Cell Carcinoma, Gastric Esophageal Junction
Phase: 2
View Details on ClinicalTrials.gov